I'll research this company before writing the profile.
Let me look into the specific tracked case and confirm size/ownership details.
Company overview. Chiaro Technology Limited, trading as Elvie, was a UK women's-health ("femtech") company incorporated in England and Wales in April 2013, registered at 63-66 Hatton Garden, London, with an innovation hub in Bristol. It was privately held with no public ticker and venture-backed, raising over $186M from investors including Octopus Ventures, BlackRock, Blume Equity and Hiro Capital; PitchBook reported a last valuation of roughly $241M. Headcount was about 170-178 near the end. On 28 March 2025 FTI Consulting was appointed administrator and sold substantially all business and assets to Willow Blossom Holdco Limited, a subsidiary of US-based Willow Innovations Inc., for £6.1M, with 178 employees transferring under TUPE.
Products / operations. Elvie designed and sold connected consumer medical devices for women. Lines included the Elvie Trainer (smart Kegel / pelvic-floor trainer, its first product); the Elvie Pump (silent in-bra wearable electric breast pump, 2018); the Elvie Stride (hospital-grade wearable pump, 2021); and Elvie Rise, an app-connected bouncer/bassinet shown at CES in January 2025. The Pump and Stride hold FDA 510(k) clearances. Products sold via elvie.com and retailers such as Target, Walmart and Amazon.
Patent-litigation posture. An operating company and net defendant, not a patent assertion entity or shell licensor. The tracked database lists one suit, in which it was defendant: Shenzhen Root Technology Co., Ltd. et al. v. Chiaro Technology, Ltd. d/b/a Elvie (W.D. Wash., Seattle, filed 28 April 2023). No plaintiff-side suits are tracked. It was not passive, however — it counterclaimed for infringement of its own patents.
Notable cases / context. In that case, Momcozy-affiliated plaintiffs sought a declaratory judgment that Elvie's US 11,357,893 ("Breast Pump System") was not infringed; Elvie counterclaimed on the '893 and '380 patents against Momcozy products, and Shenzhen Root filed IPR2024-01296 against the '380 patent. The case was stayed in April 2025 pending Elvie's administration and a Delaware Chapter 15 recognition proceeding (In re Chiaro Technology Limited, Bankr. D. Del. No. 25-10691). Context: a separate 2023 patent dispute with Willow Innovations and Dao Health was resolved by Willow's acquisition of Elvie's assets.